435801
Licofelone, Potassium Salt, Monohydrate
別名:
2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl, 2,3-dihydro-1H-pyrrolizine-5-yl)-acetic acid, ML3000, ML-3000, COX-1 Inhibitor V, FLAP Inhibitor II, mPGES-1 Inhibitor II
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
Form:
white powder
Solubility:
soluble (DMSO (100 mg/ml))
form
white powder
Quality Segment
storage condition
OK to freeze
solubility
soluble (DMSO (100 mg/ml))
storage temp.
−20°C
General description
A cell-permeable, orally active arylpyrrolizine carboxylate that is both structurally and pharmacologically similar to, but less potent than, MK-886 (Cat. No. 475889). Both MK-886 and Licofelone effectively suppress cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2 (IC50 = 0.8, 6, and >30 µM, respectively, by Licofelone), and both compounds suppress cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation (IC50 = 0.18 to 3.6 µM against ionophore-stimulated bovine and human PMNL LB4 production by Licofelone) by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (No inhibition up to 10 µM Licofelone). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, Licofelone does not cause gastrointestinal damages when applied in vivo.
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。